Catapult announces sale of R5 to Aescia

Life-sciences company Catapult has announced its sale of R5 Pharmaceuticals, a manufacturer of medicines and clinical-trial materials, to Aescia Pharmaceuticals, a supplier of active pharmaceutical ingredients.